Constitutive Plasminogen Activator Inhibitor 1 (PAI-1) Biosynthesis in Human Hep G2 Hepatoma Cells Is Maintained by an Autocrine Factor

Summary

We studied the production of PAI-1 by human Hep G2 hepatoma cells. When culturing these cells in fresh medium (FM), PAI-1 accumulation rate was not linear: PAI-1 antigen after 24 h was 200 ng/10⁶ cells while in subsequent 24 h periods, it was on average 1,000 ng/10⁶ cells. Culture of Hep G2 cells in regular changes of a 12 h conditioned medium (CM) obtained from other Hep G2, instead of in FM, resulted in a 2-fold higher PAI-1 accumulation. In cells incubated in FM, PAI-1 mRNA declined rapidly after medium change and returned to basal levels after 24 h. In contrast, PAI-1 mRNA remained relatively stable when CM was used. The acute phase mediator interleukin 6 (IL-6) was not responsible for the autocrine stimulation of PAI-1: neither IL-6 nor antibodies to IL-6 altered the observed variations in PAI-1 expression. Our studies suggest the presence of an unknown PAI-1 stimulating factor.

• References

• 1 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
• 2 Jørgensen M, Bonnevie-Nielsen V. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175-80
• 3 Pralong G, Calandra T, Glauser M-P, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemostas 1989; 61: 459-62
• 4 Hesselvik JF, Blombôck M, Brodin B, Mailer R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17: 724-33
• 5 Hamsten A, De Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombôck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ******ü: 3-8
• 6 Rocha E, Alfaro MJ, Páramo JA, Cañadell JM. Preoperative identification of patients at high risk of deep venous thrombosis despite prophylaxis in total hip replacement. Thromb Haemostas 1988; 59: 93-5
• 7 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Progr Hemostas Thromb 1988; 9: 87-115
• 8 Kruithof EKO. Plasminogen activator inhibitor type 1: Biochemical, biological and clinical aspects. Fibrinolysis 1988; 2 Supp. 2 59-70
• 9 Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19
• 10 Alessi MC, Juhan-Vague I, Kooistra T, De Clerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-4
• 11 Kooistra T, Bosma PJ, Tons HAM, Van Den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989; 62: 723-8
• 12 Lucore CL, Fujii S, Wun T-C, Sobel BE, Billadello JJ. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J Biol Chem 1988; 263: 15845-8
• 13 Fujii S, Lucore CL, Hopkins WE, Billadello JJ, Sobel BE. Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implications. Am J Cardiol 1989; 63: 1505-11
• 14 Kruithof EKO, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-53
• 15 Gonda TJ, Sheiness DK, Bishop JM. Transcripts from the cellular homologs of retroviral oncogenes – distribution among chicken tissues. Mol Cell Biol 1982; 2: 617-24
• 16 Medcalf RL, Richards RI, Crawford RJ, Hamilton JA. Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by antiinflammatory glucocorticoids. EMBO J 1986; 5: 2217-22
• 17 Thomas PS. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA 1980; 77: 5201-5
• 18 Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human p-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80
• 19 Minty AJ, Alonso S, Guénet J-L, Buckingham ME. Number and organization of actin-related sequences in the mouse genome. J Mol Biol 1983; 167: 77-101
• 20 Kant JA, Lord ST, Crabtree GR. Partial mRNA sequences for human Aa, Bβ, and γ fibrinogen chains: Evolutionary and functional implications. Proc Natl Acad Sci USA 1983; 80: 3953-7
• 21 Lotz M, Zuraw BL, Carson DA, Jirik FR. Hepatocytes produce interleukin-6. Ann N Y Acad Sci 1989; 537: 509-11
• 22 Darlington GJ, Wilson DR, Revel M, Kelly JH. Response of liver genes to acute phase mediators. Ann N Y Acad Sci 1989; 537: 310-6
• 23 Juhan-Vague I, Aillaud MF, De Cock F, Philip-Joet C, Arnaud C, Serradimigni A, Collen D. The fast-acting inhibitor of tissue-type plasminogen activator is an acute phase reactant protein. In: Progress in Fibrinolysis. Vol. VII.. Davidson JF, Donati MB, Coccheri S. (eds) Churchill Livingstone, Oxford: 1985. pp 146-9
• 24 Kluft C, Verheijen JH, Jie AFH, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-10